Viking Therapeutics (VKTX) had the highest return between October 1, 2023 and February 29, 2024 by a mid-cap US stock, returning 600.5%.
| ASSET | DATE | % RETURN |
|---|---|---|
Viking Therapeutics (VKTX) | 10/1/2023 - 2/29/2024 | 600.45% |
Dave (DAVE) | 10/1/2023 - 2/29/2024 | 307.31% |
CleanSpark (CLSK) | 10/1/2023 - 2/29/2024 | 301.3% |
SoundHound AI (SOUN) | 10/1/2023 - 2/29/2024 | 258.45% |
Sezzle (SEZL) | 10/1/2023 - 2/29/2024 | 254.47% |
Trump Media & Technology (DJTWW) | 10/1/2023 - 2/29/2024 | 253.41% |
Ocular Therapeutix (OCUL) | 10/1/2023 - 2/29/2024 | 224.52% |
Kymera Therapeutics (KYMR) | 10/1/2023 - 2/29/2024 | 208.3% |
Oscar Health (OSCR) | 10/1/2023 - 2/29/2024 | 195.64% |
Avidity Biosciences (RNA) | 10/1/2023 - 2/29/2024 | 181.97% |
Immunitybio (IBRX) | 10/1/2023 - 2/29/2024 | 178.24% |
Trump Media & Technology (DJT) | 10/1/2023 - 2/29/2024 | 154.23% |
NewAmsterdam Pharma Company NV Ordinary Shares (NAMS) | 10/1/2023 - 2/29/2024 | 153.22% |
Bitfarms (BITF) | 10/1/2023 - 2/29/2024 | 150% |
Cytokinetics (CYTK) | 10/1/2023 - 2/29/2024 | 146.05% |
GeneDx (WGS) | 10/1/2023 - 2/29/2024 | 128.93% |
Powell Industries (POWL) | 10/1/2023 - 2/29/2024 | 125.23% |
Abercrombie & Fitch (ANF) | 10/1/2023 - 2/29/2024 | 124.34% |
Scholar Rock (SRRK) | 10/1/2023 - 2/29/2024 | 119.86% |
BigBearai (BBAI) | 10/1/2023 - 2/29/2024 | 116.77% |
Tarsus Pharmaceuticals (TARS) | 10/1/2023 - 2/29/2024 | 116.67% |
Ondas (ONDS) | 10/1/2023 - 2/29/2024 | 107.86% |
Merus (MRUS) | 10/1/2023 - 2/29/2024 | 107% |
Banco Macro SA B ADR (BMA) | 10/1/2023 - 2/29/2024 | 105.96% |
TG Therapeutics (TGTX) | 10/1/2023 - 2/29/2024 | 103.79% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.
